Bristol-Myers CEO talks new acquisitions: ‘We are writing the next chapter of this company'

Bristol-Myers Squibb (BMS) CEO highlighted the company’s recent acquisitions in an interview. BMS announced three multi-billion-dollar acquisitions, including RayzeBio, Mirati Therapeutics, and Karuna Therapeutics. The CEO expressed excitement about the deal with Karuna, as it would help accelerate BMS’s business in neuropsychology. Karuna’s new medication, KarXT, is expected to treat schizophrenia and psychosis in Alzheimer’s patients. The drug is unique due to its high efficacy without some common side effects. The CEO believes these acquisitions offer attractive commercial opportunities and potential improvements in the lives of patients with Alzheimer’s disease.